Free Newsletter
Grassley probes dog-drug relaunch
It's not just human drug safety that gets Sen. Chuck Grassley into letter-writing mode. When the FDA decided to let a reformulated version of a Wyeth heartworm drug for dogs back onto the market, Grassley fired off a missive to Commissioner Andrew von Eschenbach. What he's worried about is: a. whether the new formula was actually tested on dogs (he alleges the tests were only done on guinea pigs), and b. whether any of the agency meetings about putting the drug, ProHeart, back up for sale involved FDA safety officials. Considering the way people reacted to the big pet food recall last spring, Grassley's vigilance on behalf of U.S. canines could win him some friends in the dog-owner set.
The pharma set? Not so much. Grassley's letter put a safety spin on what Wyeth probably hoped would be an uneventful, but successful reintroduction of ProHeart. The company pulled the previous version of the med in 2004 after reports that 500 dogs died after taking it. Then, Congress held hearings into the FDA's handling of the drug when a staffer said she'd raised questions about its safety--but her superiors shot her down. The new formula, in fact, is coming out under a restricted-distribution program, and its label includes warnings to refrain from administering it within a month of a vaccine.
- read the CNN Money story
Comments
I AM THE MANAGING DIRECTOR OF JOHNSON BROWN dog pharmacy STORES INC.
KINDLY BE INFORM THAT I WILL LIKE TO ORDER THE TITLE BELLOW
Dog Multivitamins.....50 bottle
ADDRESS........................DELIVERY.................................
JOHNSON BROWN dog pharmacy STORES INC
NAME:JOHNSON BROWN
ADDRES 4 ODUNLAMI LANE
CITY; LAGOS ISLAND
LAGOS STATE
ZIP CODE; 23401
COUNTRY; NIGERIA
PHONE...23470 86335304
MY METHOD OF PAYMENT WILL BE WITH MY CREDIT CARD , SO CALCULATE THE TOTAL COST OF THE ORDER AND THE SHIPPING COST TO MY ADDRESS BELOW..........AWAITING TO RECEIVE FROM YOU SOON
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: